Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes it a top stock to buy and hold for dividend investors -- arguably one of the better ones on the market. There are plenty of reasons to invest in the stock.
Abbott Laboratories (ABT) Gets a Buy from Wells Fargo
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report),
Abbott Laboratories stock underperforms Wednesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Abbott
Laboratories
' diabetes care segment recently added new
products
to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
However, sales of these
products
started declining as the outbreak receded, leading to more uneven revenue growth for the company. Throughout it all, one of
Abbott
Laboratories
' segments has been ...
Abbott Laboratories stock outperforms competitors on strong trading day
Shares of Abbott Laboratories ABT advanced 1.06% to $117.63 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.13% to 5,633.09 and the Dow Jones Industrial Average DJIA rising 0.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
2d
on MSN
Piper Sandler initiates Abbott Laboratories with "overweight" rating, $131 PT
Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...
pharmaphorum
1d
A history of Abbott and AbbVie
"
Abbott
Laboratories
began its 125th year with approximately ... "For our shareholders, we are developing the kind of essential, life-enhancing
products
that will ensure the enduring growth ...
2d
Buy Rating on Abbott Laboratories: Undervalued with Strong Growth Prospects Despite NEC Litigation
Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...
Zacks.com on MSN
2d
Abbott Stock Hurt by Macroeconomic Issues & FX Headwind
Abbott ABT is facing a challenging business environment globally. Unfavorable foreign exchange impact continues to impede ...
2d
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...
Fox Business
16d
abbott laboratories
is questioning
Abbott Laboratories
' business practices after ... shortage that is leaving Americans scrambling to find the
product
.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback